Xencor Inc (NASDAQ:XNCR) Major Shareholder Sells $756,564.00 in Stock
Xencor Inc (NASDAQ:XNCR) major shareholder Ronin Capital, Llc sold 26,800 shares of Xencor stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $28.23, for a total transaction of $756,564.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
NASDAQ:XNCR opened at $28.77 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.39 and a current ratio of 8.39. The company has a fifty day moving average of $32.18 and a two-hundred day moving average of $35.17. The stock has a market capitalization of $1.71 billion, a PE ratio of 63.93 and a beta of 1.36. Xencor Inc has a fifty-two week low of $19.35 and a fifty-two week high of $46.33.
Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Monday, February 24th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.05. The company had revenue of $3.52 million during the quarter, compared to analysts’ expectations of $6.73 million. Xencor had a net margin of 17.15% and a return on equity of 4.23%. Research analysts forecast that Xencor Inc will post -1.85 earnings per share for the current year.
Several analysts have commented on XNCR shares. BidaskClub cut shares of Xencor from a “buy” rating to a “hold” rating in a research note on Tuesday, December 31st. ValuEngine upgraded shares of Xencor from a “hold” rating to a “buy” rating in a research note on Tuesday, March 3rd. Royal Bank of Canada started coverage on shares of Xencor in a research note on Thursday, January 30th. They set an “outperform” rating and a $44.00 price objective for the company. Mizuho restated a “buy” rating and set a $52.00 price objective on shares of Xencor in a research note on Monday, February 17th. Finally, Guggenheim upgraded shares of Xencor from a “neutral” rating to a “buy” rating and set a $43.00 target price for the company in a research note on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $44.33.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Further Reading: The primary rules of Elliott Wave theory
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.